Interindividual variation in response to xenobiotic exposure established in precision-cut human liver slices

Toxicology

Volumn 323, Issue , 2014, Pages 61-69

  Jetten, Marlon J A ^a   Claessen, Sandra M ^a   Dejong, Cornelis H C ^a   Lahoz, Agustin ^b   Castell, José V ^b   van Delft, Joost H M ^a   Kleinjans, Jos C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Acetaminophen; Bayesian network; Carcinogens; Interindividual variation; Precision cut liver slices

Indexed keywords

2 NITROFLUORENE; AFLATOXIN B1; BENZO[A]PYRENE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE M1; PARACETAMOL;

ARTICLE; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION; GENOTOXICITY; HUMAN; LIVER SLICE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACETAMINOPHEN; BAYESIAN NETWORK; CARCINOGENS; INTERINDIVIDUAL VARIATION; PRECISION-CUT LIVER SLICES;

ACETAMINOPHEN; AFLATOXIN B1; BENZO(A)PYRENE; CELL SURVIVAL; COMET ASSAY; CYTOCHROME P-450 ENZYME SYSTEM; DNA DAMAGE; FLUORENES; GENE EXPRESSION; GLUTATHIONE TRANSFERASE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER; NAD(P)H DEHYDROGENASE (QUINONE); XENOBIOTICS;

EID: 84903459328     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.06.007     Document Type: Article

References (60)

1. Arakawa S., Maejima T., Fujimoto K., Yamaguchi T., Yagi M., Sugiura T., Atsumi R., Yamazoe Y. Resistance to acetaminophen-induced hepatotoxicity in glutathione S-transferase Mu 1-null mice. J. Toxicol. Sci. 2012, 37(3):595-605.
2. Bauer E., Guo Z., Ueng Y.F., Bell L.C., Zeldin D., Guengerich F.P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 1995, 8(1):136-142.
3. Behseta S., Berdyyeva T., Olson C.R., Kass R.E. Bayesian correction for attenuation of correlation in multi-trial spike count data. J. Neurophysiol. 2009, 101(4):2186-2193.
4. Buchard A., Eefsen M., Semb S., Andersen S.E., Morling N., Bendtsen F., Larsen F.S., Dalhoff K. The role of the glutathione S-transferase genes GSTT1, GSTM1, and GSTP1 in acetaminophen-poisoned patients. Clin. Toxicol. (Phila) 2012, 50(1):27-33.
5. Butterworth B.E., Smith-Oliver T., Earle L., Loury D.J., White R.D., Doolittle D.J., Working P.K., Cattley R.C., Jirtle R., Michalopoulos G., et al. Use of primary cultures of human hepatocytes in toxicology studies. Cancer Res. 1989, 49(5):1075-1084.
6. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol. Lett. 2006, 162(1):16-28.
7. Cazzalini O., Scovassi A.I., Savio M., Stivala L.A., Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat. Res. 2010, 704(1-3):12-20.
8. Chang T.K., Chen J., Pillay V., Ho J.Y., Bandiera S.M. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol. Sci. 2003, 71(1):11-19.
9. da Silva J., de Freitas T.R.O., Marinho J.R., Speit G., Erdtmann B. An alkaline single-cell gel electrophoresis (COMET) assay for environmental biomonitoring with native rodents. Genet. Mol. Biol. 2000, 23(1):241-245.
10. de Graaf I.A., Olinga P., de Jager M.H., Merema M.T., de Kanter R., van de Kerkhof E.G., Groothuis G.M. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc. 2010, 5(9):1540-1551.
11. Dejong C.H.C., Garden O.J. Neoplasms of the liver. Advanced Surgical Practice 2003, 146-156. Greenwich Medical Media, London. A.A. Majid, A. Kingsnorth (Eds.).
12. Dinkova-Kostova A.T., Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 2010, 501(1):116-123.
13. Doi A.M., Patterson P.E., Gallagher E.P. Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme expression in human prenatal and adult liver. Toxicol. Appl. Pharmacol. 2002, 181(1):48-59.
14. Dong H., Dalton T.P., Miller M.L., Chen Y., Uno S., Shi Z., Shertzer H.G., Bansal S., Avadhani N.G., Nebert D.W. Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1: differing responses to dietary benzo[a]pyrene as proof of principle. Mol. Pharmacol. 2009, 75(3):555-567.
15. Dybing E., Holme J.A., Gordon W.P., Soderlund E.J., Dahlin D.C., Nelson S.D. Genotoxicity studies with paracetamol. Mutat. Res. 1984, 138(1):21-32.
16. Eaton D.L., Gallagher E.P. Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 1994, 34:135-172.
17. Ellinger-Ziegelbauer H., Stuart B., Wahle B., Bomann W., Ahr H.J. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol. Sci. 2004, 77(1):19-34.
18. Endo K., Uno S., Seki T., Ariga T., Kusumi Y., Mitsumata M., Yamada S., Makishima M. Inhibition of aryl hydrocarbon receptor transactivation and DNA adduct formation by CYP1 isoform-selective metabolic deactivation of benzo[a]pyrene. Toxicol. Appl. Pharmacol. 2008, 230(2):135-143.
19. Fujimoto T., Kitamura S., Sanoh S., Sugihara K., Yoshihara S., Fujimoto N., Ohta S. Estrogenic activity of an environmental pollutant, 2-nitrofluorene, after metabolic activation by rat liver microsomes. Biochem. Biophys. Res. Commun. 2003, 303(2):419-426.
20. Gattas G.J., Soares-Vieira J.A. Cytochrome P450-2E1 and glutathione S-transferase mu polymorphisms among Caucasians and mulattoes from Brazil. Occup. Med. (Lond) 2000, 50(7):508-511.
21. Guengerich F.P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21(1):70-83.
22. Hakura A., Suzuki S., Sawada S., Sugihara T., Hori Y., Uchida K., Kerns W.D., Sagami F., Motooka S., Satoh T. Use of human liver S9 in the Ames test: assay of three procarcinogens using human S9 derived from multiple donors. Regul. Toxicol. Pharmacol. 2003, 37(1):20-27.
23. Hardisty J.F., Brix A.E. Comparative hepatic toxicity: prechronic/chronic liver toxicity in rodents. Toxicol. Pathol. 2005, 33(1):35-40.
24. Hazai E., Vereczkey L., Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem. Biophys. Res. Commun. 2002, 291(4):1089-1094.
25. Hernandez L.G., Slob W., van Steeg H., van Benthem J. Can carcinogenic potency be predicted from in vivo genotoxicity data? A meta-analysis of historical data. Environ. Mol. Mutagen. 2011, 52(7):518-528.
26. Jaeschke H., McGill M.R., Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev. 2012, 44(1):88-106.
27. Jennen D.G., Magkoufopoulou C., Ketelslegers H.B., van Herwijnen M.H., Kleinjans J.C., van Delft J.H. Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol. Sci. 2010, 115(1):66-79.
28. Jetten M.J., Kleinjans J.C., Claessen S.M., Chesne C., van Delft J.H. Baseline and genotoxic compound induced gene expression profiles in HepG2 and HepaRG compared to primary human hepatocytes. Toxicol. In Vitro 2013, 27(7):2031-2040.
29. Kamdem L.K., Meineke I., Godtel-Armbrust U., Brockmoller J., Wojnowski L. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem. Res. Toxicol. 2006, 19(4):577-586.
30. Kappers W.A., van Och F.M., de Groene E.M., Horbach G.J. Comparison of three different in vitro mutation assays used for the investigation of cytochrome P450-mediated mutagenicity of nitro-polycyclic aromatic hydrocarbons. Mutat. Res. 2000, 466(2):143-159.
31. Lahoz A., Donato M.T., Castell J.V., Gomez-Lechon M.J. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Curr. Drug Metab. 2008, 9(1):12-19.
32. Lahoz A., Donato M.T., Picazo L., Gomez-Lechon M.J., Castell J.V. Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry. Toxicol. In Vitro 2007, 21(7):1247-1252.
33. Lamba V., Panetta J.C., Strom S., Schuetz E.G. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J. Pharmacol. Exp. Ther. 2010, 332(3):1088-1099.
34. Langie S.A., Knaapen A.M., Brauers K.J., van Berlo D., van Schooten F.J., Godschalk R.W. Development and validation of a modified comet assay to phenotypically assess nucleotide excision repair. Mutagenesis 2006, 21(2):153-158.
35. Lecureur V., Guillouzo A., Fardel O. Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Carcinogenesis 1996, 17(5):1157-1160.
36. Lee W.M. Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatology 2007, 46(4):966-970.
37. Ma Q., Lu A.Y. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos. 2007, 35(7):1009-1016.
38. Mathijs K., Brauers K.J., Jennen D.G., Boorsma A., van Herwijnen M.H., Gottschalk R.W., Kleinjans J.C., van Delft J.H. Discrimination for genotoxic and nongenotoxic carcinogens by gene expression profiling in primary mouse hepatocytes improves with exposure time. Toxicol. Sci. 2009, 112(2):374-384.
39. Mitchell J.R., Thorgeirsson S.S., Potter W.Z., Jollow D.J., Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther. 1974, 16(4):676-684.
40. Moller L. In vivo metabolism and genotoxic effects of nitrated polycyclic aromatic hydrocarbons. Environ. Health Perspect. 1994, 102(Suppl. 4):139-146.
41. Morand S., Buchillier V., Maurer F., Bonny C., Arsenijevic Y., Munier F.L., Schorderet D.F. Induction of apoptosis in human corneal and HeLa cells by mutated BIGH3. Invest. Ophthalmol. Vis. Sci. 2003, 44(7):2973-2979.
42. Plazar J., Hreljac I., Pirih P., Filipic M., Groothuis G.M. Detection of xenobiotic-induced DNA damage by the comet assay applied to human and rat precision-cut liver slices. Toxicol. In Vitro 2007, 21(6):1134-1142.
43. Powell H., Kitteringham N.R., Pirmohamed M., Smith D.A., Park B.K. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998, 8(5):411-421.
44. Qin L.F., Ng I.O. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum. Pathol. 2001, 32(8):778-784.
45. Rannug U., Holme J.A., Hongslo J.K., Sram R. International Commission for Protection against Environmental Mutagens and Carcinogens. An evaluation of the genetic toxicity of paracetamol. Mutat. Res. 1995, 327(1-2):179-200.
46. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 2003, 31(5):533-539.
47. Rhodes S.P., Otten J.N., Hingorani G.P., Hartley D.P., Franklin R.B. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. J. Pharmacol. Toxicol. Methods 2011, 63(3):223-226.
48. Rodriguez-Antona C., Donato M.T., Pareja E., Gomez-Lechon M.J., Castell J.V. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch. Biochem. Biophys. 2001, 393(2):308-315.
49. Schweikl H., Taylor J.A., Kitareewan S., Linko P., Nagorney D., Goldstein J.A. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993, 3(5):239-249.
50. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270(1):414-423.
51. Slob W., Moerbeek M., Rauniomaa E., Piersma A.H. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints. Toxicol. Sci. 2005, 84(1):167-185.
52. Spielberg S.P. Acetaminophen toxicity in human lymphocytes in vitro. J. Pharmacol. Exp. Ther. 1980, 213(2):395-398.
53. Taniguchi Y., Choi P.J., Li G.W., Chen H., Babu M., Hearn J., Emili A., Xie (2010) Quantifying X.S.E. coli proteome and transcriptome with single-molecule sensitivity in single cells. Science 2010, 329(5991):533-538.
54. Thummel K.E., Lee C.A., Kunze K.L., Nelson S.D., Slattery J.T. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharmacol. 1993, 45(8):1563-1569.
55. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13(4):227-232.
56. Wang D., Jiang Z., Shen Z., Wang H., Wang B., Shou W., Zheng H., Chu X., Shi J., Huang W. Functional evaluation of genetic and environmental regulators of p450 mRNA levels. PLoS One 2011, 6(10):e24900.
57. Westlind A., Malmebo S., Johansson I., Otter C., Andersson T.B., Ingelman-Sundberg M., Oscarson M. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 2001, 281(5):1349-1355.
58. Wilczynski B., Dojer N. BNFinder: exact and efficient method for learning Bayesian networks. Bioinformatics 2009, 25(2):286-287.
59. Zhao L., Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab. Rev. 2011, 43(1):41-52.
60. Zhou S.F., Wang B., Yang L.P., Liu J.P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev. 2010, 42(2):268-354.